Alzheimer's Disease Clinical Trials in Los Angeles

Showing 101-120 of 175 trials

Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)

NCT03088956

The objectives of the study are to; (1) estimate the change in disease -related cognitive decline over 1 year on a battery of cognitive tests administered to participants with early-stage symptomatic Behavioral Variant Frontotemporal Dementia (bvFTD) phenotypic variant; (2) identify the cognitive test or brief battery of cognitive tests which are the most sensitive to detect bvFTD progression; (3) determine the optimal schedule of administration of cognitive tests to detect bvFTD progression; (4) evaluate the relationship between cognitive tests and measures of behavior, function, caregiver's burden, quality of life (QOL); and (5) obtain blood samples for genetic and exploratory biomarkers correlations.

Frontotemporal DementiaBehavioral Variant Frontotemporal Dementia

Biogen47 participantsStarted Jan 2018

Birmingham, Alabama, United States • Los Angeles, California, United States • Boca Raton, Florida, United States +9 more locations

TERMINATEDPhase 3< 1 mile

Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease

NCT01127633

This study is an open-label extension study in Alzheimer's patients who have completed participation in either solanezumab Clinical Trial H8A-MC-LZAM (NCT00905372) or H8A-MC-LZAN (NCT00904683).

Alzheimer's Disease

Eli Lilly and Company1,457 participantsStarted Dec 2010

Phoenix, Arizona, United States • Sun City, Arizona, United States • Tucson, Arizona, United States +144 more locations

Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)

Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease

Alzheimer's Disease Trials in Other Cities

A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Statins in Cerebral Blood Flow and Neuronal Activity--A Pilot Study

A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease

SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05

Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil

Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease

A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)

A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease

Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease

18F-AV-1451 Autopsy Study

A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired Subjects

Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study

A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease

Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease

Other Conditions in Los Angeles